Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Australia and New Zealand Banking Group Ltd. Capital/Financing Update 2019

Dec 19, 2019

10425_rns_2019-12-19_92515721-eb61-41e5-89fd-49ce0ca1f766.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Australia and New Zealand Banking Group Limited ( ANZ )

ABN

11 005 357 522

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

  • 1 +Class of +securities issued or to 1. Options to subscribe for ordinary shares be issued 2. Fully paid ordinary shares

  • 2 Number of[+] securities issued or 1. 168,066 options to be issued (if known) or 2. 1,592,499 fully paid ordinary shares maximum number which may be issued

  • See chapter 19 for defined terms.

Appendix 3B Page 1

04/03/2013

3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

1. 168,066 options

  • 168,066 Performance Rights (options) exercisable from 17 December 2023 and before the close of business on 16 December 2025 (after which date the Rights will lapse), unless further deferred, at a zero exercise price and subject to the following performance conditions:

  • The Performance Rights will be granted in two tranches:

  • Tranche 1 (75% of the grant) will be subject to a relative Total Shareholder Return (TSR) performance condition with a Select Financial Services comparator group; and

  • Tranche 2 (25% of the grant) will be subject to an Absolute Compound Annual Growth Rate Total Shareholder Return (CAGR TSR) performance condition.

  • Tranche 1

  • The proportion of Performance Rights that become exercisable in tranche 1 will depend upon the TSR achieved by ANZ relative to the companies in the comparator group, measured over the four year performance period from 22 November 2019 to, and calculated as at, the end of the four year performance period (close of business on 21 November 2023).

  • Performance equal to the median TSR of the comparator group will result in half of the Performance Rights becoming exercisable on 17 December 2023.

  • Performance above median will result in further Performance Rights for tranche 1 becoming exercisable on 17 December 2023, increasing on a straight-line basis until all of the Performance Rights for that tranche become exercisable where ANZ’s TSR is at or above the 75th percentile of TSR in the comparator group. Where ANZ’s performance falls between two of the comparators TSR is measured on a prorata basis. The actual relative level of TSR, rather than simple ranking, will determine the level of vesting.

  • Tranche 2

  • The proportion of Performance Rights that become exercisable in tranche 2 will depend upon the Absolute Compound Annual Growth Rate (CAGR) TSR achieved by ANZ relative to the CAGR TSR targets set by the Board of ANZ for this award measured over the four year performance period (commencing 22 November 2019).

  • Performance equal to 8.5% CAGR TSR will result in half the Performance Rights becoming exercisable (50% vesting) on 17 December 2023.

  • Performance above 8.5% CAGR TSR will result in further Performance Rights becoming exercisable, increasing on a straight-line basis until all of the Performance Rights become exercisable where ANZ’s CAGR TSR is 12.75% (100% vesting) on 17 December 2023.

  • Where ANZ’s performance falls between 8.5% and 12.75%, Absolute CAGR TSR is measured on a pro-rata basis.

  • The Board retains discretion to adjust the Absolute CAGR TSR hurdle in exceptional circumstances to ensure that employees are neither advantaged nor disadvantaged by matters outside management’s control that materially affect achievement of the ATSR performance condition.

Tranches 1 and 2

  • An averaging calculation is used for TSR over a 90 trading day period for start and end values in order to reduce share price volatility.

  • Each TSR performance hurdle for the two tranches of Performance Rights will only be tested once at the end of the four year performance period. The percentage of Performance Rights in a tranche that vest as a result of the TSR calculation will be fixed. If the Performance Rights do not pass the performance hurdle on the testing date, they will lapse.

  • Each tranche is measured independently.

  • 1,592,499 fully paid ordinary shares Terms of the shares will be the same as the terms of existing ordinary shares.

  • See chapter 19 for defined terms.

Appendix 3B Page 3

04/03/2013

4 Do the[+] securities rank equally 1. 168,066 options in all respects from the[+] issue date with an existing[+] class of Inapplicable, as no ANZ options are currently quoted[+] securities? listed save that in the event of exercise the resulting ordinary shares issued will rank If the additional[+] securities do equally in all respects from the date of allotment with the existing class of quoted securities. not rank equally, please state:  the date from which they do 2. 1,592,499 fully paid ordinary shares  the extent to which they participate for the next Yes dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 1. 168,066 options – zero exercise price 2. 1,592,499 fully paid ordinary shares at nil consideration 6 Purpose of the issue 1. 168,066 Performance Rights issued to Mr (If issued as consideration for Elliott for the purposes set out in the notice the acquisition of assets, clearly convening ANZ’s 2019 Annual General identify those assets) Meeting. 2. 1,592,499 fully paid ordinary shares issued under the Bonus Option Plan (BOP). 6a Is the entity an[+] eligible entity No that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the[+] securities the subject of this Appendix 3B , and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6c Number of[+] securities issued N/A without security holder approval under rule 7.1 6d Number of[+] securities issued N/A with security holder approval under rule 7.1A

6e
Number of+securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
6f
Number of+securities issued
under an exception in rule 7.2
6g
If+securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
+issue date and both values.
Include the source of the VWAP
calculation.
6h
If+securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which
valuation
of
consideration was released to
ASX Market Announcements
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
N/A
N/A

N/A
N/A
N/A

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

  1. 168,066 options – 17/12/19 2. 1,592,499 fully paid ordinary shares – 18/12/19

Cross reference: item 33 of Appendix 3B.

  • See chapter 19 for defined terms.

Appendix 3B Page 5

04/03/2013

  • 8 Number and +class of all +securities quoted on ASX ( including the +securities in section 2 if applicable)
Number +Class
2,836,177,422
11,200,000
16,100,000
9,701,791
16,220,000
9,310,782
Fully paid ordinary
shares
ANZ Capital Notes 1
ANZ Capital Notes 2
ANZ Capital Notes 3
ANZ Capital Notes 4
ANZ Capital Notes 5

USD1,250,000,000 2.05 per cent. Covered Bond due May 2020

EUR750,000,000 0.625 per cent. Fixed Rate Notes due February 2023

CNY2,500,000,000 4.75 per cent. Fixed Rate Subordinated Notes due January 2025

SGD500,000,000 3.75 per cent. Fixed Rate Subordinated Notes due March 2027

AUD200,000,000 4.75 per cent. Fixed Rate Subordinated Notes due May 2027

EUR1,000,000,000 1.125 per cent. Fixed Rate Subordinated Notes due November 2029

AUD225,000,000 4.75 per cent. Fixed Rate Subordinated Notes due September 2032

USD1,000,000,000 Perpetual Subordinated Contingent Convertible Securities

Number +Class 9 Number and +class of all 6,925,982 Options on issue +securities not quoted on ASX ( including the +securities in section 2 if applicable)

  • 10 Dividend policy (in the case of a 1. Not applicable trust, distribution policy) on the 2. Same as existing fully paid ordinary shares increased capital (interests)

Part 2 - Pro rata issue

art 2 - Pro rata issue
11
Is
security
holder
approval
required?
12
Is the issue renounceable or non-
renounceable?
13
Ratio in which the+securities
will be offered
14
+Class of+securities to which the
offer relates
15
+Record
date
to
determine
entitlements
16
Will
holdings
on
different
registers (or subregisters) be
aggregated
for
calculating
entitlements?
17
Policy for deciding entitlements
in relation to fractions
18
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing
date
for
receipt
of
acceptances or renunciations
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
  • See chapter 19 for defined terms.

Appendix 3B Page 7

04/03/2013

20
Names of any underwriters
21
Amount of any underwriting fee
or commission
22
Names of any brokers to the
issue
23
Fee or commission payable to the
broker to the issue
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders
25
If the issue is contingent on
security holders’ approval, the
date of the meeting
26
Date entitlement and acceptance
form and offer documents will be
sent to persons entitled
27
If the entity has issued options,
and the terms entitle option
holders
to
participate
on
exercise, the date on which
notices will be sent to option
holders
28
Date rights trading will begin (if
applicable)
29
Date rights trading will end (if
applicable)
30
How do security holders sell
their entitlements_in full_through
a broker?
31
How do security holders sell_part_
of their entitlements through a
broker
and
accept
for
the
balance?
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
  • See chapter 19 for defined terms.

Appendix 3B Page 8

04/03/2013

  • 32 How do security holders dispose of their entitlements (except by sale through a broker)?

N/A

  • 33 +Issue date

N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

  • 34 Type of[+] securities ( tick one )

  • (a) +Securities described in Part 1

  • (b)[All other ][+][securities ]

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

  • 35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

  • 36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

  • 1 - 1,000

  • 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

  • 37 A copy of any trust deed for the additional[+] securities

  • See chapter 19 for defined terms.

Appendix 3B Page 9

04/03/2013

Entities that have ticked box 34(b)

38
Number of+securities for which
+quotation is sought
39
+Class of+securities for which
quotation is sought
40
Do the+securities rank equally in
all respects from the+issue date
with an existing+class of quoted
+securities?
If the additional+securities do not
rank equally, please state:
 the date from which they do
 the extent to which they
participate
for
the
next
dividend, (in the case of a
trust, distribution) or interest
payment
 the extent to which they do
not rank equally, other than in
relation to the next dividend,
distribution
or
interest
payment
41
Reason for request for quotation
now
Example: In the case of restricted securities, end
of restriction period
(if issued upon conversion of
another+security, clearly identify
that other+security)
42
Number
and
+class
of
all
+securities
quoted
on
ASX
(_including_the+securities in clause
38)
N/A
N/A
N/A
N/A
Number +Class
N/A N/A
  • See chapter 19 for defined terms.

Appendix 3B Page 10

04/03/2013

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: .......................................................... Date: 19 December 2019 Company Secretary

Print name: Simon Pordage

== == == == ==

  • See chapter 19 for defined terms.

Appendix 3B Page 11

04/03/2013